Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: Mathematics, statistics, and their integration

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 6, Issue 3, 2014, Pages 239-253

  Agur, Zvia ^a,b   Elishmereni, Moran ^a,b   Kheifetz, Yuri ^a,b  

^a Institute for Medical Biomathematics Isarel   (Israel)

^b Optimata Ltd Zichron Ya'akov   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CHEMOTHERAPY INDUCED NEUTROPENIA; CHONDROSARCOMA; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; MATHEMATICAL MODEL; METASTASIS; NEUTROPENIA; NONHUMAN; PERSONALIZED MEDICINE; PREDICTOR VARIABLE; PROSTATE CANCER; PROTOCOL COMPLIANCE; STATISTICAL MODEL; SURVIVAL RATE; BAYES THEOREM; IMMUNOTHERAPY; METABOLISM; MORTALITY; NEOPLASMS; THEORETICAL MODEL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BAYES THEOREM; BIOLOGICAL MARKERS; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; MODELS, THEORETICAL; NEOPLASMS; NEUTROPENIA;

EID: 84898775269     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.1263     Document Type: Article

References (66)

1. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008, 44:946-953.
2. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007, 96:213-268.
3. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011, 8:587-596.
4. Rhea JM, Molinaro RJ. Cancer biomarkers: surviving the journey from bench to bedside. MLO Med Lab Obs 2011, 43:10-12 16, 18; quiz 20, 22.
5. Sawyers CL. The cancer biomarker problem. Nature 2008, 452:548-552.
6. Woodcock J. The prospects for "personalized medicine" in drug development and drug therapy. Clin Pharmacol Ther 2007, 81:164-169.
7. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010, 102:1462-1467.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70.
9. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.
10. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 2010, 7:309-317.
11. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat 2009, 19:530-542.
12. Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med 2010, 7:33-47.
13. Simon R. Advances in clinical trial designs for predictive biomarker discovery and validation. Curr Breast Cancer Rep 2009, 1:216-221.
14. Agur Z, Vuk-Pavlovic S. Mathematical modeling in immunotherapy of cancer: personalizing clinical trials. Mol Ther 2012, 20:1-2.
15. Dutton G. Companion Dx and personalized medicine. Wall Street Biobeat 2012. Available at: http://www.genengnews.com/gen-articles/companion-dx-and-personalized-medicine/4577/. (Accessed January 28, 2014).
16. Abrahams E, Ginsburg GS, Silver M. The personalized medicine coalition: goals and strategies. Am J Pharmacogenomics 2005, 5:345-355.
17. Ahn ER, Wang E, Gluck S. Is the improved efficacy of trastuzumab and lapatinib combination worth the added toxicity? A discussion of current evidence, recommendations, and ethical issues regarding dual HER2-targeted therapy. Breast Cancer (Auckl) 2012, 6:191-207.
18. Agur Z. Biomathematics in the development of personalized medicine in oncology. Future Oncol 2006, 2:39-42.
19. Rubinow SI, Lebowitz JL. Model of cell kinetics with applications to the acute myeloblastic leukemic state in man. Biosystems 1977, 8:265-266.
20. Schmidt W, Eisen M. Mathematical Models in Cell Biology and Cancer Chemotherapy. Lecture Notes in Biomathematics, vol. 30. Springer-Verlag, Berlin-Heidelberg-New York 1979. IX, 431 S., 70 Abb., 17 Tab., DM 39. Biom J 1981, 23:519-520.
21. Hart D, Shochat E, Agur Z. The growth law of primary breast cancer as inferred from mammography screening trials data. Br J Cancer 1998, 78:382-387.
22. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977, 61:1307-1317.
23. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 1978, 62:1117-1133.
24. Agur Z, Arnon R, Schechter B. Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs. Math Biosci 1988, 92:1-15.
25. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004, 100:228-237.
26. Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer 2009, 101(Suppl 1):S18-22.
27. Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer 2009, 101(Suppl 1):S23-26.
28. Foley C, Mackey MC. Mathematical model for G-CSF administration after chemotherapy. J Theor Biol 2009, 257:27-44.
29. Shochat E, Rom-Kedar V. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling. Clin Cancer Res 2008, 14:6354-6363.
30. Vainstein V, Ginosar Y, Shoham M, Ranmar DO, Ianovski A, Agur Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol 2005, 234:311-327.
31. Vainstein V, Ginosaur Y, Shoham M, Ianovski A, Rabinovich A, Kogan Y, Selitser Z, Agur Z. Improving cancer therapy by doxorubicin and granulocyte colony-stimulating factor: insights from a computerized model of human granulopoiesis. Nat Phenom 2006, 1:70-80.
32. Ozawa K, Minami H, Sato H. Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients. Cancer Sci 2007, 98:1985-1992.
33. van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 2000, 6:1365-1371.
34. Vainas O, Ariad S, Amir O, Mermershtain W, Vainstein V, Kleiman M, Inbar O, Ben-Av R, Mukherjee A, Chan S, et al. Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model. Br J Cancer 2012, 107:814-822.
35. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996, 24:153-172.
36. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 2004, 10:1976-1983.
37. Arakelyan L, Vainstein V, Agur Z. A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. Angiogenesis 2002, 5:203-214.
38. Agur Z, Arakelyan L, Daugulis P, Ginosar Y. Hopf point analysis for angiogenesis models. Disc Contin Dyn Syst Ser B 2004, 4:29-38.
39. Arakelyan L, Merbl Y, Agur Z. Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids. Eur J Cancer 2005, 41:159-167.
40. Gorelik B, Ziv I, Shohat R, Wick M, Hankins WD, Sidransky D, Agur Z. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 2008, 68:9033-9040.
41. Hirata Y, Akakura K, Higano CS, Bruchovsky N, Aihara K. Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression. J Mol Cell Biol 2012, 4:127-132.
42. Hirata Y, Tanaka G, Bruchovsky N, Aihara K. Mathematically modelling and controlling prostate cancer under intermittent hormone therapy. Asian J Androl 2012, 14:270-277.
43. Forsberg JA, Wedin R, Bauer HC, Hansen BH, Laitinen M, Trovik CS, Keller JO, Boland PJ, Healey JH. External validation of the Bayesian Estimated Tools for Survival (BETS) models in patients with surgically treated skeletal metastases. BMC Cancer 2012, 12:493.
44. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol 2002, 20:1368-1374.
45. Galfano A, Novara G, Iafrate M, Cavalleri S, Martignoni G, Gardiman M, D'Elia C, Patard JJ, Artibani W, Ficarra V. Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 2008, 80:113-123.
46. Gobburu JV, Marroum PJ. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clin Pharmacokinet 2001, 40:883-892.
47. de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet 2005, 44:147-173.
48. Evene E, Chatelut E, Tranchand B, Canal P, Lochon I, Iliadis A, Ardiet CJ. Bayesian estimation of pharmacokinetic parameters of etoposide. Bull Cancer 1997, 84:699-703.
49. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981, 9:503-512.
50. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981, 9:635-651.
51. Tranchand B, Amsellem C, Chatelut E, Freyer G, Iliadis A, Ligneau B, Trillet-Lenoir V, Canal P, Lochon I, Ardiet CJ. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 1999, 43:316-322.
52. Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol 2008, 48:632-649.
53. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J 2008, 10:552-559.
54. Ette EI, Williams PJ. Pharmacometrics : The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley & Sons; 2007.
55. Grasela TH, Dement CW, Kolterman OG, Fineman MS, Grasela DM, Honig P, Antal EJ, Bjornsson TD, Loh E. Pharmacometrics and the transition to model-based development. Clin Pharmacol Ther 2007, 82:137-142.
56. Bhattaram VA, Bonapace C, Chilukuri DM, Duan JZ, Garnett C, Gobburu JV, Jang SH, Kenna L, Lesko LJ, Madabushi R, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 2007, 81:213-221.
57. Goldberger MJ, Singh N, Allerheiligen S, Gobburu JV, Lalonde R, Smith B, Ryder S, Yozviak A. ASCPT Task Force for advancing pharmacometrics and integration into drug development. Clin Pharmacol Ther 2010, 88:158-161.
58. Lee JY, Garnett CE, Gobburu JV, Bhattaram VA, Brar S, Earp JC, Jadhav PR, Krudys K, Lesko LJ, Li F, et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet 2011, 50:627-635.
59. Wallin JE, Friberg LE, Karlsson MO. A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Prog Biomed 2009, 93:283-291.
60. Wallin JE, Friberg LE, Karlsson MO. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol 2010, 106:234-242.
61. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 2012, 38:890-903.
62. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17:2341-2354.
63. Agur Z, Vuk-Pavlovic S. Personalizing immunotherapy: balancing predictability and precision. Oncoimmunology 2012, 1:1169-1171.
64. Kogan Y, Halevi-Tobias K, Elishmereni M, Vuk-Pavlovic S, Agur Z. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. Cancer Res 2012, 72:2218-2227.
65. Kronik N, Kogan Y, Elishmereni M, Halevi-Tobias K, Vuk-Pavlovic S, Agur Z. Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS One 2010, 5:e15482.
66. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005, 11:4469-4478.